前列腺SBRT中尿道内剂量与泌尿毒性强烈相关:23项前瞻性临床试验汇总分析
该研究汇总23项前瞻性临床试验共2232例前列腺癌SBRT患者,分析尿道最大剂量指标(MUDM)与泌尿毒性的关系。结果显示MUDM的EQD2与急性G2+、晚期G2+及晚期G3+泌尿毒性均显著相关,且相关性优于处方剂量。结论提示前列腺SBRT应关注尿道剂量,降低尿道剂量的方法值得进一步研究。
要点
- MUDM的EQD2与急性G2+、晚期G2+及晚期G3+泌尿毒性均显著相关。
- MUDM与泌尿毒性的相关性优于处方剂量。
- 在研究剂量范围内,MUDM每增加1 Gy,急性G2+和晚期G2+毒性分别增加0.8%和1.0%。
核心结论
- 前列腺癌SBRT中尿道受照剂量与泌尿毒性密切相关。
- 高剂量前列腺SBRT时应关注尿道剂量,尿道剂量减低方法值得进一步研究。
研究设计与样本
- 检索MEDLINE(PubMed)截至2020年8月的前列腺SBRT前瞻性研究,纳入记录尿道最大剂量指标(MUDM)者。
- 共纳入23项独特研究、2232例患者,MUDM的EQD2范围为69-141.75 Gy(α/β=3 Gy)。
- 中位随访时间范围为3至67个月(中位32个月)。
- 采用逻辑回归和加权Pearson相关模型评估泌尿毒性率与MUDM的关联。
主要发现
- 逻辑回归显示MUDM的EQD2与急性G2+(OR 1.02,P<.001)、晚期G2+(OR 1.03,P<.0001)及晚期G3+(OR 1.04,P=.003)泌尿毒性显著相关。
- 加权Pearson相关显示MUDM与所有评估的泌尿毒性终点相关性均优于处方剂量,包括急性G2+(r=0.51,P=.02)、晚期G2+(r=0.9,P<.0001)及晚期G3+(r=0.7,P=.003)。
- 多变量分析校正年龄、前列腺大小、膀胱剂量学及基线泌尿功能后,仍证实泌尿结局与MUDM的关联。
- 在研究剂量范围内,MUDM每增加1 Gy,急性G2+和晚期G2+毒性分别增加0.8%和1.0%。
关键数值与推荐
- MUDM的EQD2范围为69-141.75 Gy(α/β=3 Gy)。
- 急性G2+泌尿毒性:OR 1.02(P<.001),r=0.51(P=.02)。
- 晚期G2+泌尿毒性:OR 1.03(P<.0001),r=0.9(P<.0001)。
- 晚期G3+泌尿毒性:OR 1.04(P=.003),r=0.7(P=.003)。
- MUDM每增加1 Gy,急性G2+和晚期G2+毒性分别增加0.8%和1.0%。
临床怎么用
- 前列腺癌SBRT计划设计时应关注尿道内剂量,尤其在高剂量照射时。
- 可将尿道最大剂量指标作为评估泌尿毒性风险的参考。
- 尿道剂量减低方法值得进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Clinical trials assessing evaluation prostate stereotactic body radiation therapy (SBRT) have used a wide range of allowed doses to the intraprostatic urethra, but the relationship between urethral dose and urinary toxicity has not been thoroughly evaluated. The goal of this study was to characterize urinary toxicity outcomes according to urethral dose administered during prostate SBRT. METHODS AND MATERIALS: The MEDLINE (PubMed) database was searched for published prospective studies of prostate SBRT through August 2020 that documented a maximum urethral dose metric (MUDM). Reported acute and late urinary toxicity rates were collected. Logistic regression and weighted Pearson correlation models were used to assess associations between urinary toxicity rates and MUDM. RESULTS: Twenty-three unique studies (n = 2232 patients) met the inclusion criteria and included a wide range of MUDMs (equivalent dose in 2 Gy fractions [EQD2]: 69-141.75 Gy; α/β = 3 Gy). The median follow-up ranged from 3 to 67 months (median, 32 months). On logistic regression analysis, the MUDM EQD2 was significantly associated with multiple urinary toxicity endpoints, including acute grade (G) 2+ (odds ratio [OR], 1.02; P < .001), late G2+ (OR, 1.03; P < .0001), and late G3+ (OR, 1.04; P = .003) urinary toxicity. On weighted Pearson correlation analysis, the MUDM was more closely associated with all evaluated urinary toxicity endpoints than prescription dose, including acute G2+ (r = 0.51; P = .02), late G2+ (r = 0.9; P < .0001), and late G3+ toxicity (r = 0.7; P = .003). Multivariate analysis accounting for age, prostate size, bladder dosimetry, and baseline urinary function confirmed associations between urinary outcomes and MUDM. Within the studied dose range, each increase of 1 Gy to the MUDM corresponded to a 0.8% and 1.0% increase in acute G2+ and late G2+ toxicity, respectively. CONCLUSIONS: Radiation dose to the urethra correlates closely with urinary toxicity in patients with prostate cancer treated with SBRT. Attention should be paid to the urethral dose when delivering prostate SBRT to high doses, and approaches for urethral dose reduction warrant further investigation.
引用
- Leeman JE, Chen YH, Catalano P, et al. Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials. Int J Radiat Oncol Biol Phys. 2021. PMID: 34711459. doi:10.1016/j.ijrobp.2021.06.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。